Secukinumab-induced paradoxical hidradenitis suppurativa.
Francisco Jose Navarro-TriviñoRicardo Sanchez-PareraRicardo Ruiz VillaverdePublished in: Dermatologic therapy (2019)
Paradoxical reactions during treatment with biological agents may be defined as an appearance or exacerbation of a pathological condition that usually responds to this class of drug. Typical examples of paradoxical adverse effect are, among others, palmoplantar pustular and psoriasiform reactions or HS, in patients during a treatment of rheumatoid arthitis or IBD mainly. A few reports have been described an exacerbation of psoriasis1, palmoplantar pustular, or pustular psoriasis eruption with secukinumab. Marasca et al. highlights the immunological complexity that surrounds autoinflammatory diseases showing the potential double pathogenetic face of secukinumab in HS, describing a case of secukinumab-induced HS and a case of HS caused by adalimumab treatment and controlled by secukinumab therapy. Real world evidence and results from clinical trials with secukinumab for HS, will possibly show the real role that anti-IL-17 drugs play in this complex disease.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- hidradenitis suppurativa
- clinical trial
- chronic obstructive pulmonary disease
- disease activity
- end stage renal disease
- high glucose
- drug induced
- diabetic rats
- newly diagnosed
- chronic kidney disease
- ejection fraction
- stem cells
- oxidative stress
- emergency department
- systemic lupus erythematosus
- adverse drug
- prognostic factors
- juvenile idiopathic arthritis
- randomized controlled trial
- study protocol
- peritoneal dialysis
- mechanical ventilation
- phase ii
- patient reported